All News

Battling DIR Fees

The profitability of both chain and independent pharmacies is being affected by direct and indirect remuneration fees that insurers are retroactively charging pharmacies after filling Medicare Part D prescriptions.

In patients with COPD who have a history of exacerbations, a once-daily treatment regimen of combined fluticasone furoate and vilanterol was associated with fewer exacerbations than usual care without a greater risk of serious adverse events

New Mexico's state motto is “The Land of Enchantment,” but it might also be dubbed the The Land of Opportunity. Pharmacists here are increasingly breaking barriers to deliver frontline, provider care services in an environment that fosters innovations for the profession, students, and patients.

PBM giants cut drug expenses

When Express Scripts and CVS Health announced their 2017 formularies on August 1, a common theme emerged among the healthcare giants: several blockbuster drugs will be removed from both companies’ formularies and lower-cost options such as biosimilars are being embraced.

FDA approved Onzetra Xsail (Avanir Pharmaceuticals Inc.)- a fast-acting, low-dose sumatriptan dry powder formulation for the acute treatment of migraine with or without aura in adults.

Americans spend billions of dollars on products to address specific hair and scalp concerns each year-whether that be color, condition, or appearance.

Community pharmacists are caught in the middle of a battle between patients and their health insurers over how the federal government defines medical foods and how patients are paying for them.

Helping pharmacists perform at the top of their licenses and be reimbursed for services such as medication therapy management (MTM) are among the goals of the National Community Pharmacist Association’s (NCPA) Innovation Center.

Patients are willing to use antibiotics without contacting a medical professional, according to a study published in Antimicrobial Agents and Chemotherapy.

Are You Safe at Work?

Retail pharmacies are in the news a lot these days. Unfortunately, it is not the kind of news anyone wants to hear.

Physicians and pharmacists welcomed FDA’s recent approval of etanercept-szzs (Erelzi), a biosimilar to Amgen’s top-selling Enbrel for rheumatoid arthritis, plaque psoriasis, and other inflammatory conditions.